Hit discovery and hit-to-lead approaches.

Hit discovery technologies range from traditional high-throughput screening to affinity selection of large libraries, fragment-based techniques and computer-aided de novo design, many of which have been extensively reviewed. Development of quality leads using hit confirmation and hit-to-lead approaches present their own challenges, depending on the hit discovery method used to identify the initial hits. In this paper, we summarize common industry practices adopted to tackle hit-to-lead challenges and review how the advantages and drawbacks of different hit discovery techniques could affect the various issues hit-to-lead groups face.

[1]  Renaldo Mendoza,et al.  ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens. , 2005, Journal of the American Chemical Society.

[2]  Tudor I. Oprea,et al.  Pursuing the leadlikeness concept in pharmaceutical research. , 2004, Current opinion in chemical biology.

[3]  P. Hajduk,et al.  Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. , 2006, Journal of medicinal chemistry.

[4]  Manfred E. Wolff,et al.  Burger's Medicinal chemistry , 1980 .

[5]  Ajay N. Jain,et al.  Virtual screening in lead discovery and optimization. , 2004, Current opinion in drug discovery & development.

[6]  Matthew A Cooper,et al.  Advances in membrane receptor screening and analysis , 2004, Journal of molecular recognition : JMR.

[7]  Ivan Huc,et al.  Using an Enzyme's Active Site To Template Inhibitors This work was supported by the Centre National de la Recherche Scientifique and by the Ecole Polytechnique (predoctoral fellowship to R.N.). We thank Prof. Jean-Marie Lehn for stimulating discussions. , 2001, Angewandte Chemie.

[8]  Wolfgang Jahnke,et al.  Second-site NMR screening and linker design. , 2003, Current topics in medicinal chemistry.

[9]  D. Epps,et al.  A competitive fluorescence assay to measure the reactivity of compounds. , 2001, Analytical biochemistry.

[10]  Gang Liu,et al.  Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. , 2003, Journal of the American Chemical Society.

[11]  Daniel A. Erlanson,et al.  Fragment‐Based Drug Discovery. , 2004 .

[12]  D. A. Annis,et al.  A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures. , 2004, Journal of the American Chemical Society.

[13]  Steve Steiner,et al.  Missing link , 1989 .

[14]  Dustin J Maly,et al.  Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Christopher W Murray,et al.  Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.

[16]  Patrick J. Curran,et al.  An affinity selection–mass spectrometry method for the identification of small molecule ligands from self-encoded combinatorial libraries: Discovery of a novel antagonist of E. coli dihydrofolate reductase , 2004 .

[17]  Hugo O Villar,et al.  Using NMR for ligand discovery and optimization. , 2004, Current opinion in chemical biology.

[18]  Roland Heckendorn,et al.  2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist , 1999, Neuropharmacology.

[19]  Ju Gao,et al.  Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 2. , 2004, Bioorganic & medicinal chemistry letters.

[20]  M. Uesugi,et al.  [Discovering high-affinity ligands for proteins: SAR by NMR]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[21]  L. Mayr,et al.  SpeedScreen: The “Missing Link” between Genomics and Lead Discovery , 2004, Journal of biomolecular screening.

[22]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[23]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[24]  Andrew Douglas Baxter.  Hit-to-Lead Studies: The Discovery of Potent, Orally Active, Thiophenecarboxamide IKK-2 Inhibitors. , 2004 .

[25]  P. Hajduk,et al.  Novel inhibitors of Erm methyltransferases from NMR and parallel synthesis. , 1999, Journal of medicinal chemistry.

[26]  Paul G Wyatt,et al.  Detection of ligands from a dynamic combinatorial library by X-ray crystallography. , 2003, Angewandte Chemie.

[27]  Ajay,et al.  The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. , 1999, Chemistry & biology.

[28]  Mark Washburn,et al.  3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. , 2003, Journal of medicinal chemistry.

[29]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[30]  Richard A Ward,et al.  Structure-based virtual screening for low molecular weight chemical starting points for dipeptidyl peptidase IV inhibitors. , 2005, Journal of medicinal chemistry.

[31]  P. Hajduk,et al.  NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. , 1997, Journal of medicinal chemistry.

[32]  Csilla Horváth,et al.  Oxamides as novel NR2B selective NMDA receptor antagonists. , 2004, Bioorganic & medicinal chemistry letters.

[33]  D. Kostrewa,et al.  Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.

[34]  M Katharine Holloway,et al.  Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. , 2004, Journal of medicinal chemistry.

[35]  Karl A. Walter,et al.  ChemInform Abstract: Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR. , 1997 .

[36]  V. L. Rath,et al.  Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. , 2000, Chemistry & biology.

[37]  A. Woods,et al.  Homogeneous proximity tyrosine kinase assays: scintillation proximity assay versus homogeneous time-resolved fluorescence. , 1999, Analytical biochemistry.

[38]  John Unitt,et al.  Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[39]  Jean-Pierre Gotteland,et al.  Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. , 2005, Journal of medicinal chemistry.

[40]  C Nicholas Hodge,et al.  Streamlined system for purifying and quantifying a diverse library of compounds and the effect of compound concentration measurements on the accurate interpretation of biological assay results. , 2004, Analytical chemistry.

[41]  Kam Y. J. Zhang,et al.  A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design , 2005, Nature Biotechnology.

[42]  Anil Vasudevan,et al.  Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 2. , 2004, Bioorganic & medicinal chemistry letters.

[43]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[44]  Eric Vangrevelinghe,et al.  Molecular Informatics as an enabling in silico technology platform for drug discovery , 2004 .

[45]  P. Hajduk,et al.  NMR-based screening in drug discovery , 1999, Quarterly Reviews of Biophysics.

[46]  C. Craik,et al.  Design and synthesis of novel inhibitors of gelatinase B. , 2002, Bioorganic & medicinal chemistry letters.

[47]  Mark E Schurdak,et al.  Affinity-based screening techniques for enhancing lead discovery. , 2004, Current opinion in drug discovery & development.

[48]  Anna Vulpetti,et al.  3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. , 2004, Journal of medicinal chemistry.

[49]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[50]  Gang Liu,et al.  Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands. , 2003, Journal of medicinal chemistry.

[51]  Jean M. Severin,et al.  Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. , 2004, Journal of medicinal chemistry.

[52]  C. Pargellis,et al.  Discovery and characterization of a substrate selective p38alpha inhibitor. , 2004, Biochemistry.

[53]  E B Reilly,et al.  Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. , 2001, Journal of medicinal chemistry.

[54]  Neera Borkakoti,et al.  Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening. , 2003, Bioorganic & medicinal chemistry letters.

[55]  Jordi Mestres,et al.  Identification of "latent hits" in compound screening collections. , 2003, Journal of medicinal chemistry.

[56]  A. Gołębiowski,et al.  Lead compounds discovered from libraries: part 2. , 2003, Current opinion in chemical biology.

[57]  J. Ellman,et al.  Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors. , 2005, Journal of the American Chemical Society.

[58]  スティーヴン・トム,et al.  The novel compounds , 1998 .

[59]  Christopher W Murray,et al.  Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. , 2005, Journal of medicinal chemistry.

[60]  Gergely M Makara,et al.  Improving success rates for lead generation using affinity binding technologies , 2005, Current Opinion in Biotechnology.

[61]  W. Delano,et al.  In situ assembly of enzyme inhibitors using extended tethering , 2003, Nature Biotechnology.

[62]  Nestler Hp.  Hit to Lead Success Stories--IBC Conference: Effective chemistry strategies for reducing attrition rates and speeding lead compounds into the pipeline. 31 January-1 February 2005, San Diego, CA, USA. , 2005 .

[63]  C. Brochu,et al.  Discovery of small-molecule inhibitors of the ATPase activity of human papillomavirus E1 helicase. , 2004, Journal of medicinal chemistry.

[64]  R. Stroud,et al.  Site-directed ligand discovery. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Vicki L. Nienaber,et al.  Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.

[66]  A. Eliseev,et al.  Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Martin Braddock,et al.  Hit-to-Lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.

[68]  József Nagy,et al.  Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[69]  Bernd Rinn,et al.  Quantifying Bioactivity on a Large Scale: Quality Assurance and Analysis of Multiparametric Ultra-HTS Data , 2005 .

[70]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[71]  Stephen D. Pickett,et al.  Research Papers) Design of a Compound Screening Collection for use in High Throughput Screening , 2004 .

[72]  P. Beaulieu,et al.  Non‐Nucleoside Inhibitors of the Hepatitis C Virus NS5B Polymerase: Discovery and Preliminary SAR of Benzimidazole Derivatives. , 2004 .

[73]  Alison R. Gregro,et al.  Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). , 2004, Journal of medicinal chemistry.

[74]  R. Griffey,et al.  SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. , 2002, Journal of medicinal chemistry.

[75]  S D Pickett,et al.  Design of a compound screening collection for use in high throughput screening. , 2004, Combinatorial chemistry & high throughput screening.

[76]  J. Proudfoot.  Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. , 2002, Bioorganic & medicinal chemistry letters.

[77]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[78]  Bryan Roberts,et al.  Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.

[79]  Ping Li,et al.  Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. , 2004, Journal of medicinal chemistry.

[80]  Anna Vulpetti,et al.  3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization. , 2005, Journal of medicinal chemistry.

[81]  J. Madwed,et al.  Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. , 2002, Journal of medicinal chemistry.

[82]  Edward R Zartler,et al.  Fragonomics: fragment-based drug discovery. , 2005, Current opinion in chemical biology.